OncLive TV

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

OncLive interviewed experts at the State of the Science Summits™ in March 2020 on the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Ziad Bakouny, MD, MSc, discusses the utility of checkpoint inhibitors in renal cell carcinoma with sarcomatoid differentiation.

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center–James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Ivy P. Altomare, MD, discusses treatment options for patients with immune thrombocytopenia purpura.

Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

David P. Carbone, MD, PhD, director of the Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center–James, provides perspective on the novel coronavirus 2019 (COVID-19).

Richa Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.

Amit G. Singal, MD, discusses systemic therapies in hepatocellular carcinoma.